Publisher Health

People in the United Kingdom with folic acid prescriptions were 1.5 times more likely to get COVID-19. They were also 2.6 times more likely to die from COVID-19 compared to the control group. Those are the findings of a new study from UC Davis Health and the University of Alabama at Birmingham.
The research, published in the journal BMJ Open, also found that having a prescription for the antifolate drug methotrexate mitigated the negative impact of folic acid on COVID-19 when folic acid and methotrexate were given together.
The research team studied a large cohort of patients enrolled in the UK BioBank, a major biomedical database containing health information from half a million people.
“We examined whether COVID-19 diagnosis and death were related to the large doses of folic acid — five times the safe upper limit — prescribed to patients for a variety of medically approved indications. We found that the risk of becoming infected and dying from COVID-19 was significantly greater in the group treated with folic acid,” said Ralph Green, an expert on B vitamins. Green is a distinguished professor in the UC Davis Department of Pathology and Laboratory Medicine and co-senior author of the study.
Folic acid and COVID-19
Folic acid is a synthetic form of vitamin B9, also known as folate. Low levels of B9 are associated with health conditions such as an increased risk of heart disease, stroke and birth defects.

It began with a spat over crudités. It has escalated into one Senate hopeful who is openly mocking another’s health after a stroke.Dr. Mehmet Oz, the Republican nominee for Senate in Pennsylvania, has taunted his Democratic rival, Lt. Gov. John Fetterman, about his stroke recovery, suddenly thrusting an issue both candidates had tiptoed around into a central theme of one of the most watched races of the year.Mr. Fetterman said on Tuesday that he would not participate in a debate in early September, implying that his recovery from his stroke in May was not complete enough for him to perform at the peak of his abilities. His decision came after a day of goading by the Oz campaign.“As I recover from this stroke and improve my auditory processing and speech, I look forward to continuing to meet with the people of Pennsylvania,” Mr. Fetterman, who returned to campaigning this month, said in a statement.Earlier in the day, the Oz campaign had issued a list of bogus “concessions” it would make if Mr. Fetterman agreed to a Sept. 6 debate hosted by Pittsburgh’s KDKA-TV, including “We will pay for any additional medical personnel he might need to have on standby” and “At any point, John Fetterman can raise his hand and say, ‘Bathroom break!’”More Coverage of the 2022 Midterm ElectionsEvidence Against a Red Wave: Since the fall of Roe v. Wade, it’s hard to see the once-clear signs of a Republican advantage. A strong Democratic showing in a New York special election is the latest example.G.O.P.’s Dimming Hopes: Republicans are still favored in the fall House races, but former President Donald J. Trump and abortion are scrambling the picture in ways that distress party insiders.A Surprise Race: Senator Michael Bennet, a Democrat seeking re-election in Colorado, is facing an unexpected challenge from Joe O’Dea, a novice Republican emphasizing more moderate positions.Campaign Ads: In what critics say is a dangerous gamble, Democrats are elevating far-right candidates in G.O.P. primaries, believing they’ll be easier to defeat in November. We analyzed the ads they’re using to do it.The ugly turn in the race, whose outcome could help determine which party controls the Senate after the fall elections, opened Dr. Oz, who left a career as a heart surgeon and TV celebrity to run for office, to accusations of resorting to low blows. While there is a long tradition in American politics of candidates’ questioning rivals’ health and fitness for office, Dr. Oz seized on the issue as he has been reviving his struggling candidacy.The attacks have pried open an issue that the Fetterman campaign has sought to control — Mr. Fetterman’s health — by avoiding free-for-all questioning from the news media or voters since the candidate’s return to campaigning this month.After suffering a stroke days before the primary, Mr. Fetterman had a pacemaker and defibrillator implanted. His campaign at first released little information. Eventually, it disclosed he had been diagnosed with a heart condition, cardiomyopathy, which makes it harder for the heart to pump blood to the body. In a statement at the time, Mr. Fetterman’s doctor said he should be able to campaign and serve in the Senate without problems if he takes his recovery “very seriously.”Before returning to the campaign trail on Aug. 12, Mr. Fetterman acknowledged he sometimes dropped or slurred words but was improving daily.At an Aug. 23 appearance in Pittsburgh, his speech was halting, and he sometimes searched perceptibly for the right words. Conservative news outlets and commentators seized on clips from the appearance to portray Mr. Fetterman as unfit.For months during his convalescence, the Fetterman campaign consisted largely of insulting Dr. Oz on social media, including calling him a carpetbagger from New Jersey. That effort paid off with millions of online interactions and a flood of donations.Then, when Mr. Fetterman made fun of Dr. Oz for a resurfaced video in which Dr. Oz was shopping for what he called “crudités” in the vegetable aisle, to demonstrate the impact of inflation, the Oz campaign returned fire in a different way.“If John Fetterman had ever eaten a vegetable in his life, then maybe he wouldn’t have had a major stroke and wouldn’t be in the position of having to lie about it constantly,” an Oz spokeswoman, Rachel Tripp, said in a statement.The Oz campaign continued to bring up the issue of Mr. Fetterman’s health to attack him for not committing to a series of five debates. Dr. Oz insinuated that his opponent was shirking a confrontation.Asked in a radio interview Tuesday whether his campaign went too far in attacking Mr. Fetterman for causing his stroke by skipping vegetables, Dr. Oz struck what seemed like false solicitude: “John Fetterman should be allowed to recover fully, and I will support his ability as someone going through a difficult time to get ready.” Later in the day, the Oz campaign embraced an openly sarcastic tone when it released its list of debate “concessions.”Mr. Fetterman reacted strongly. “Today’s statement from Dr. Oz’s team made it abundantly clear that they think it is funny to mock a stroke survivor,” Mr. Fetterman said in a statement. “I chose not to participate in this farce.”“My recovery may be a joke to Dr. Oz and his team, but it’s real for me,” he added.Democratic strategists in Pennsylvania not affiliated with the Fetterman campaign said that questions about his health or appearance in debates were unlikely to shake his support, which two recent polls put at an edge of four or five percentage points over his rival.“As a Democrat, I would rather have Oz talking about debates — an issue that few voters care about — than talking about inflation,” said J.J. Balaban, a Democratic strategist. “And Fetterman’s stroke was widely reported, so voters’ concerns may already be baked in the cake.”Many Republican base voters have been slow to coalesce behind Dr. Oz because of suspicions that he is neither a true conservative nor a member of the Make America Great Again movement. Seeing influential conservatives take up the issue of Mr. Fetterman’s health — including the Fox News host Laura Ingraham and the commentator Ben Shapiro — may help secure those Republicans’ support for Dr. Oz.However, there is also the potential for backlash against Dr. Oz. On Wednesday, Mr. Fetterman released a video in which he asks a roomful of voters, “How many of you have had a big health challenge in your life?”“Can you even imagine that if you had a doctor that was mocking your illness or ridiculing that?” he added. “Well, here we are.”

Published17 hours agoSharecloseShare pageCopy linkAbout sharingImage source, Getty ImagesUS life expectancy has fallen to the lowest level seen since 1996, continuing a steep decline largely driven by the Covid-19 pandemic. Government data showed life expectancy at birth now stands at 76.1 compared to 79 in 2019. That is the steepest two-year decline in a century. Covid-19 was the main contributing factor, according to US Centres for Disease Control and Prevention data.Life expectancy of Native Americans and Alaska Natives fell by two years. According to the provisional data, life expectancy fell by 2.7 years between 2019 and 2021.The statistics show that Covid-19 accounted for 50% of the decline between 2020 and 2021. Between 2019 and 2020, the pandemic contributed to 74% of the decline. Unintentional injuries – a term which also includes drug overdoses – reached record highs in 2021 and contributed to 15.9% of the decline. Deaths from heart disease, chronic liver disease and cirrhosis and suicides were also significant contributors.The fall in US life expectancy was particularly pronounced among Native Americans and Alaska Natives.Since 2019, life expectancy among this demographic has dropped by 6.6 years, more than twice that of the wider US population. The CDC statistics also highlight stark differences in life expectancy between men and women. For men, life expectancy fell by about a year to 73.2 in 2021 while women’s life expectancy fell by 10 months to 79.1A separate set of 2020 data released last week also showed significant geographical differences across the country. Life expectancy in Hawaii is the highest at 80.7, compared to 71.9 years in Mississippi. Life expectancy in the US is among the lowest of developed nations around the world. In the UK, for example, life expectancy stood at around 79 for men and 82.9 for women in 2020 after it fell for the first time in 40 years.According to the latest available statistics from the World Bank, Hong Kong and Japan have the world’s highest life expectancies at around 85 followed by Singapore at 84. Life expectancy in countries including Switzerland, Australia, Norway hovers at around 83.More on this storyUS life expectancy has biggest fall since WW221 July 2021Life expectancy is down but what does this mean?23 September 2021Dr Anthony Fauci to step down after 38 years22 August

The expansion of telehealth services during the COVID-19 pandemic was associated with individuals staying in treatment longer and reducing their risk of medically treated overdose, according to a new study.
Published today in JAMA Psychiatry, this study was a collaborative effort led by researchers at the National Center for Injury Prevention and Control, a part of the Centers for Disease Control and Prevention (CDC); the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH); and the Centers for Medicare & Medicaid Services (CMS).
In this national study, researchers analyzed data among 175,778 Medicare beneficiaries from September 2018 to February 2021. The analysis examined the receipt of telehealth services, medications for opioid use disorder (MOUD), and experiencing a medically treated overdose among individuals with opioid use disorder (OUD) starting a new episode of care prior to the pandemic compared to those during the pandemic.
“Strategies to increase access to care and MOUD receipt and retention are urgently needed, and the results of this study add to the growing research documenting the benefits of expanding the use of telehealth services for people with OUD,” said lead author Christopher M. Jones, Pharm.D., Dr.P.H., acting director of the National Center for Injury Prevention and Control at the CDC. “The findings from this collaborative study also highlight the importance of working across agencies to identify successful approaches to address the escalating overdose crisis.”
Among the key findings from this study: Data analyzed from two groups of Medicare beneficiaries, one group initiating an episode of OUD-related care before the COVID-19 pandemic and one initiating care during the COVID-19 pandemic, and found that those in the COVID-19 pandemic group were more likely to receive OUD-related telehealth services compared to the pre-pandemic group (19.6% compared to 0.6%) and were more likely to receive MOUD (12.6% compared to 10.8%). Among the COVID-19 pandemic group, receipt of OUD-related telehealth services was associated with significantly better MOUD treatment retention and lower risk of medically treated overdose compared to those not receiving OUD-related telehealth services, lending support for permanently implementing access to telehealth services.”The expansion of telehealth services for people with substance use disorders during the pandemic has helped to address barriers to accessing medical care for addiction throughout the country that have long existed,” said Wilson Compton, M.D., M.P.E, deputy director of the National Institute on Drug Abuse and senior author of the study. “Telehealth is a valuable service and when coupled with medications for opioid use disorder can be lifesaving. This study adds to the evidence showing that expanded access to these services could have a longer-term positive impact if continued.”
Although the study did find that receiving OUD-related telehealth services was generally associated with beneficial outcomes, the study also determined some groups were less likely to receive these services, including non-Hispanic black persons and those living in the South. These outcomes underscore the need for future efforts to focus on eliminating the digital divide and reducing underlying inequities in access to care and services.
“The COVID-19 pandemic was an unexpected shock to the US healthcare system, which consequently offered a unique opportunity to investigate the impact of healthcare delivery methods on health outcomes among those who were newly diagnosed with OUD. The findings showed that telehealth improved the receipt and retention of MOUD, suggesting that this method of healthcare delivery may address common barriers to OUD-related treatment such as transportation and perceived stigma associated with OUD,” said lead analyst Carla Shoff, Ph.D., social science research analyst at CMS.
This study serves as a supportive resource towards maintaining access to telehealth services for patients with OUD as it demonstrates that Medicare beneficiaries and providers used the new flexibilities related to telehealth services during the COVID-19 pandemic and that these services were associated with positive impacts on patient outcomes such as MOUD treatment receipt, retention, and risk for medically treated overdose.
Story Source:
Materials provided by NIH/National Institute on Drug Abuse. Note: Content may be edited for style and length.

Two pioneering studies published simultaneously today in Nature and Genome Medicine, have identified genetic signatures explaining ethnic differences in the severity of prostate cancer, particularly in sub-Saharan Africa.
Through genetic sequencing of prostate cancer tumours from Australian, Brazilian and South African donors, the team identified a new prostate cancer taxonomy (classification scheme) and cancer drivers that not only distinguish patients by genetic ancestry, but also predict which cancers are likely to become life-threatening — a task that currently proves challenging.
“Our understanding of prostate cancer has been severely limited by a research focus on Western populations,”said senior author Professor Vanessa Hayes, genomicist and Petre Chair of Prostate Cancer Research at the University of Sydney’s Charles Perkins Centre and Faculty of Medicine and Health in Australia.
“Being of African descent, or from Africa, more than doubles a man’s risk for lethal prostate cancer. While genomics holds a critical key to unravelling contributing genetic and non-genetic factors, data for Africa has till now, been lacking.”
“Prostate cancer is the silent killer in our region,” said University of Pretoria’s Professor Riana Bornman, an international expert in men’s health and clinical lead for the Southern African Prostate Cancer Study in South Africa.
“We had to start with a grassroots approach, engaging communities with open discussion, establishing the infrastructure for African inclusion in the genomic revolution, while determining the true extent of prostate disease.”
Through sophisticated whole genome sequencing (a way of mapping the entire genetic code of cancer cells), over two million cancer-specific genomic variants were identified in 183 untreated prostate tumours from men living across the three study regions.

Astronauts are at higher risk for developing mutations — possibly linked to spaceflight — that can increase the risk of developing cancer and heart disease during their lifetimes, according to a first-of-its kind study from the Icahn School of Medicine at Mount Sinai.
A team of researchers collected blood samples from National Aeronautics and Space Administration (NASA) astronauts who flew space shuttle missions between 1998 and 2001. They discovered DNA mutations, known as somatic mutations, in the blood-forming system (hematopoietic stem cells) in all 14 astronauts studied. Their findings, published in the August issue of Nature Communications Biology, suggest that spaceflight could be associated with these mutations and emphasize the importance of ongoing blood screening of astronauts throughout their careers and during their retirement to monitor their health.
Somatic mutations are mutations that occur after a person is conceived and in cells other than sperm or egg cells, meaning they cannot be passed on to offspring. The mutations identified in this study were characterized by the overrepresentation of blood cells derived from a single clone, a process called clonal hematopoiesis (CH). Such mutations are frequently caused by environmental factors, such as exposure to ultraviolet radiation or certain chemicals, and may be a result of cancer chemo- or radiotherapy. There are few signs or symptoms associated with CH; most patients are identified after genetic testing of their blood for other diseases. Although CH is not necessarily an indicator of disease, it is associated with a higher risk for cardiovascular disease and blood cancer.
“Astronauts work in an extreme environment where many factors can result in somatic mutations, most importantly space radiation, which means there is a risk that these mutations could develop into clonal hematopoiesis. Given the growing interest in both commercial spaceflights and deep space exploration, and the potential health risks of exposure to various harmful factors that are associated with repeated or long-duration exploration space missions, such as a trip to Mars, we decided to explore, retrospectively, somatic mutation in the cohort of 14 astronauts,” said the study’s lead author David Goukassian, MD, Professor of Medicine (Cardiology) with the Cardiovascular Research Institute at Icahn Mount Sinai.
The study subjects were astronauts who flew relatively short (median 12 days) space shuttle missions between 1998 and 2001. Their median age was approximately 42 years old; roughly 85 percent were male, and six of the 14 were on their first mission. The researchers collected whole blood samples from the astronauts 10 days before their flight and on the day of landing, and white blood cells only three days after landing. The samples were stored at -80ºC for approximately 20 years.
Using DNA sequencing followed by extensive bioinformatics analyses, researchers identified 34 mutations in 17 CH-driver genes. The most frequent mutations occurred in TP53, a gene that produces a tumor-suppressing protein, and DNMT3A, one of the most frequently mutated genes in acute myeloid leukemia. However, the frequency of the somatic mutations in the genes that the researchers assessed was less than two percent, the technical threshold for somatic mutations in hematopoietic stem cells to be considered clonal hematopoiesis of indeterminate potential (CHIP). CHIP is more common in older individuals and is associated with increased risk of developing cardiovascular disease and both hematologic and solid cancer.
“Although the clonal hematopoiesis we observed was of a relatively small size, the fact that we observed these mutations was surprising given the relatively young age and health of these astronauts. The presence of these mutations does not necessarily mean that the astronauts will develop cardiovascular disease or cancer, but there is the risk that, over time, this could happen through ongoing and prolonged exposure to the extreme environment of deep space,” Dr. Goukassian said. “Through this study, we have shown that we can determine the individual susceptibility of astronauts to develop disease related to their work without any implications that can affect their ability to do their work. Indeed, our studies demonstrate the importance of early and ongoing screening to assess that susceptibility. Our recommendation is that NASA, and its medical team, screen astronauts for somatic mutations and possible clonal expansion, or regression, every three to five years, and, not less importantly, well into their retirement years when somatic mutations may expand clonally and become CHIP.”
The team’s research follows previous studies that used the same samples to identify predictive biomarkers in exosomes — small lipid-layered microscopic vesicles of nucleic acids, proteins, lipids, and metabolites that form within the cells of the human body and are subsequently released into the blood circulation, hence carrying the information from their cells of origin that reflects their intercellular condition. This feature of exosomes may qualify them as great biomarkers of health and/or disease, as well as transfer information from one cell to another at great distance in the body. When they treated human heart cells with exosomes derived from astronauts, the researchers found that the exosomes affected the biology of the vitamin D receptor, which plays a key role in bone, heart, and skeletal muscle health. They also assessed the impact of space flight on mitochondrial DNA — the genome of small organelles that supply energy to cells. In that study, the team found that the amount of cell-free mitochondrial DNA circulating in the blood of astronauts was two to 350 times higher than normal, which may lead to oxidative damage and inflammation elsewhere in the body.
“Through these studies, we have demonstrated the potential to assess the health risk of space flight among astronauts. What is important now is to conduct longitudinal retrospective and well-controlled prospective studies involving a large number of astronauts to see how that risk evolves based on continued exposure and then compare that data against their clinical symptoms, imaging, and lab results. That will enable us to make informed predictions as to which individuals are more likely to develop disease based on the phenomena we are seeing and open the door to individualized precision medicine approaches to early intervention and prevention,” said Dr. Goukassian.

Most of us think little of why we feel pleasantly full after eating a big holiday meal, why we start to cough after accidentally inhaling campfire smoke, or why we are hit with sudden nausea after ingesting something toxic. However, such sensations are crucial for survival: they tell us what our bodies need at any given moment so that we can quickly adjust our behavior.
Yet historically, very little research has been devoted to understanding these basic bodily sensations — also known as internal senses — that are generated when the brain receives and interprets input from internal organs.
Now, a team led by researchers at Harvard Medical School has made new strides in understanding the basic biology of internal organ sensing, which involves a complicated cascade of communication between cells inside the body.
In a study conducted in mice and published Aug. 31 in Nature, the team used high-resolution imaging to reveal spatial maps of how neurons in the brain stem respond to feedback from internal organs.
They found that feedback from different organs activates discrete clusters of neurons, regardless of whether this information is mechanical or chemical in nature — and these groups of neurons representing different organs are topographically organized in the brain stem. Moreover, they discovered that inhibition within the brain plays a key role in helping neurons selectively respond to organs.
“Our study reveals the fundamental principles of how different internal organs are represented in the brain stem,” said lead author Chen Ran, research fellow in cell biology at HMS.

Science has long shown that men are at greater risk for developing atrial fibrillation (AFib) than women; but it has never been fully understood why women would be protected from developing the condition. New research from the Smidt Heart Institute at Cedars-Sinai challenges this conventional wisdom by demonstrating that women — when height is accounted for — have a 50% higher risk of developing the abnormal heart rhythm disturbance when compared to men.
The novel findings, published today in the peer-reviewed journal JAMA Cardiology, suggest medical practitioners must remain vigilant in promoting AFib prevention — and early interventions — among both female and male patients.
“This is the first study to show an actual flip in the risk of atrial fibrillation,” said Christine Albert, MD, MPH, chair of the Department of Cardiology in the Smidt Heart Institute and senior author of the JAMA Cardiology study. Albert also led the national VITAL Rhythm Trial upon which these findings are based. “In this population of 25,000 individuals without prior heart disease, after adjusting for differences in height, women were at higher risk for developing AF than their male counterparts — upward of 50%.”
As Albert explains, the taller an individual is, the more at risk they are for AFib. This is why women have been shown to have a lower risk of the disease, since they tend to be shorter than men.
“Our study, however, surprisingly suggests that if a man and a woman have the same height, the woman would be more likely to develop AFib,” said Albert. “Now the question has changed: Instead of why are women protected, now we must seek to understand why women are at a higher risk.”
Atrial fibrillation is the most common type of abnormal heart rhythm and, without treatment, can lead to stroke or heart failure. Once a woman is diagnosed with AFib, she is more likely to experience one of these adverse consequences than a man, making AFib prevention exceedingly important in women.

What did the fat say to the brain? For years, it was assumed that hormones passively floating through the blood were the way that a person’s fat — called adipose tissue — could send information related to stress and metabolism to the brain. Now, Scripps Research scientists report in Nature that newly identified sensory neurons carry a stream of messages from adipose tissue to the brain.
“The discovery of these neurons suggests for the first time that your brain is actively surveying your fat, rather than just passively receiving messages about it,” says co-senior author Li Ye, PhD, the Abide-Vividion Chair in Chemistry and Chemical Biology and an associate professor of neuroscience at Scripps Research. “The implications of this finding are profound.”
“This is yet another example of how important sensory neurons are to health and disease in the human body,” says co-senior author and professor Ardem Patapoutian, PhD, who is also a Nobel laureate and a Howard Hughes Medical Institute investigator.
In mammals, adipose tissue stores energy in the form of fat cells and, when the body needs energy, releases those stores. It also controls a host of hormones and signaling molecules related to hunger and metabolism. In diseases including diabetes, fatty liver disease, atherosclerosis and obesity, that energy storage and signaling often goes awry.
Researchers have long known that nerves extend into adipose tissue, but suspected they weren’t sensory neurons that carry data to the brain. Instead, most hypothesized that the nerves in fat belonged mostly to the sympathetic nervous system — the network responsible for our fight-or-flight response, which switches on fat-burning pathways during times of stress and physical activity. Attempts to clarify the types and functions of these neurons have been difficult; methods used to study neurons closer to the surface of the body or in the brain don’t work well deep in adipose tissue, where nerves are hard to see or to stimulate.
Ye and colleagues developed two new methods that enable them to overcome these challenges. First, an imaging approach called HYBRiD turned mouse tissues transparent and allowed the team to better track the paths of neurons as they snaked into adipose tissue. The researchers discovered that nearly half of these neurons didn’t connect to the sympathetic nervous system, but instead to dorsal root ganglia — an area of the brain where all sensory neurons originate.

The agency cleared booster doses targeting Omicron subvariants, hoping to curtail a fall or winter surge.WASHINGTON — The Food and Drug Administration on Wednesday authorized the first redesign of coronavirus vaccines since they were rolled out in late 2020, setting up millions of Americans to receive new booster doses targeting Omicron subvariants as soon as next week.The agency cleared two options aimed at the BA.5 variant of Omicron that is now dominant: one made by Pfizer and its German partner BioNTech for use in people as young as 12, and the other by Moderna, for those 18 and older.Biden administration officials have argued that even as researchers work to understand how protective the new shots might be, inoculating Americans again in the coming weeks could help curb the persistently high number of infections and deaths. They have said that retooling the vaccine is likely to provide better protection against highly contagious Omicron subvariants heading into winter.An average of about 90,000 infections and 475 deaths are recorded every day around the United States, almost three years into a pandemic that has killed more than a million Americans and driven a historic drop in life expectancy.But there are also hopeful signs. Even with high case counts, fewer than 40,000 people are currently hospitalized with the virus, a decrease of 10 percent since early August and far fewer than during the Delta-driven surge last summer or the Omicron-fueled wave last winter. Deaths have also remained somewhat flat in recent weeks, a sign that vaccines are helping to prevent the worst outcomes of Covid-19.Read More on the Coronavirus PandemicBoosters: Updated coronavirus vaccines are expected soon after Labor Day. But money to distribute the shots has dried up, as America’s vaccination program is feeling the effects of a long period of retreat.Moderna’s Lawsuits: The vaccine manufacturer sued Pfizer and BioNTech, claiming that its rivals’ Covid-19 shot copied groundbreaking technology that Moderna had developed before the pandemic.Fauci to Step Down: Dr. Anthony S. Fauci, President Biden’s top medical adviser who was catapulted into the spotlight at the start of the pandemic, said he would leave government service by the end of the year.New C.D.C. Guidelines: The agency loosened its Covid-19 guidance, saying those exposed to the virus no longer need to quarantine.Ample evidence suggests that many Americans will hold back from getting the updated boosters, either because they are weary of the pandemic or may not feel urgency about an additional dose. With each new shot offered, there are fewer takers.As more companies bring workers back to offices and students return to campuses this fall, persuading Americans to get the updated booster shots will be a major challenge for the administration.The companies produced the retooled booster shots with extraordinary speed, a testament to the mRNA technology that Pfizer and Moderna have harnessed since the early months of the coronavirus outbreak. The F.D.A. advised companies just two months ago on the formulation that they should adopt for the new vaccines. By later this week, millions of those doses will be delivered to states.The tight timeline meant that the companies came to federal regulators this summer with more limited data on the redesigned boosters than a traditional review process would call for, generating some controversy. Regulators authorized the vaccine without results from human trials, which have just started.Federal officials argue that because the coronavirus is evolving so quickly, human trials would be out of date before they could deliver results that could be used in the F.D.A.’s authorization decision. Instead, they are relying on the results of mouse trials and earlier human trials by Pfizer and Moderna of reformulations aimed at previous versions of the virus. The Biden administration is casting the shots as a standard upgrade that Americans should embrace ahead of potential surges in cases this winter, just like the flu shot, which is reconfigured every year to target more current versions of the influenza virus.The new shots are arriving during a period when the White House has been largely quiet on the pandemic. President Biden has rarely commented on the virus in recent months, even after he fell ill with Covid-19 in July. The White House no longer holds regular news briefings on the federal pandemic response, like it did in the first year of the administration, a reflection of the weariness many Americans have in keeping up with Covid precautions.“Covid-19 is the third leading cause of death in the United States. And it’s as if we’ve just accepted that that is going to be the case,” said Mercedes Carnethon, an epidemiologist at Northwestern University’s Feinberg School of Medicine. “I really hope as many people as possible will seek the updated booster so we can protect those who will have a terrible outcome.”Vaccinations remain the cornerstone of the federal government’s Covid strategy, even with tests and treatments widely available. The Biden administration has ordered over 170 million doses for the fall campaign, and officials do not expect shortages in supply when the doses are rolled out.“If it’s freezing cold out and you have children, you’re going to dress them warmly. This is the concept here,” said Dr. Paul G. Auwaerter, the clinical director in the infectious diseases division at the Johns Hopkins University School of Medicine. “You’ll want to head into the respiratory season with a virus that we know has surprised us with a booster.”Exactly how protective the shots might be is still unknown, Dr. Auwaerter said. He pointed to the modest increases in neutralizing antibodies that the companies found in vaccines they tested earlier this year targeting the original form of Omicron. How antibody levels would translate to protection with the new vaccines was unclear, he added.Experts warned against trying to choose Moderna’s shot over Pfizer’s or vice versa; with research in humans just beginning, scientists are months from knowing whether one brand offers better protection than the other.Many Americans have recently been infected by variants in the Omicron family and have some protection from their bouts with the virus, a development that federal agencies may take into account when recommending how the new shots get used. An advisory committee to the Centers for Disease Control and Prevention is scheduled to meet later this week to make recommendations.“For most people the risk of death is so low at this point, because they’ve gotten infected or vaccinated, or more likely both,” said Dr. Gregory Poland, professor of medicine and infectious diseases and director of the Vaccine Research Group at the Mayo Clinic.Dr. Poland, who has advised Moderna, Pfizer and White House officials on Covid-19 vaccines, said updating booster shots the way the F.D.A. did on Tuesday amounted to a “chase your tail” strategy, tweaking the design incrementally to try to keep up with the fast-changing virus. The new boosters, he said, could potentially save some lives among the elderly and those with immune deficiencies, but were unlikely to make as substantial an impact with the rest of the population.